375 related articles for article (PubMed ID: 29197621)
1. Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
Van Helleputte L; Kater M; Cook DP; Eykens C; Rossaert E; Haeck W; Jaspers T; Geens N; Vanden Berghe P; Gysemans C; Mathieu C; Robberecht W; Van Damme P; Cavaletti G; Jarpe M; Van Den Bosch L
Neurobiol Dis; 2018 Mar; 111():59-69. PubMed ID: 29197621
[TBL] [Abstract][Full Text] [Related]
2. Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition.
Bertels Z; Singh H; Dripps I; Siegersma K; Tipton AF; Witkowski WD; Sheets Z; Shah P; Conway C; Mangutov E; Ao M; Petukhova V; Karumudi B; Petukhov PA; Baca SM; Rasenick MM; Pradhan AA
Elife; 2021 Apr; 10():. PubMed ID: 33856345
[TBL] [Abstract][Full Text] [Related]
3. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.
Benoy V; Vanden Berghe P; Jarpe M; Van Damme P; Robberecht W; Van Den Bosch L
Neurotherapeutics; 2017 Apr; 14(2):417-428. PubMed ID: 27957719
[TBL] [Abstract][Full Text] [Related]
4. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.
Krukowski K; Ma J; Golonzhka O; Laumet GO; Gutti T; van Duzer JH; Mazitschek R; Jarpe MB; Heijnen CJ; Kavelaars A
Pain; 2017 Jun; 158(6):1126-1137. PubMed ID: 28267067
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
Dawood M; Fleischer E; Klinger A; Bringmann G; Shan L; Efferth T
Pharmacol Res; 2020 Oct; 160():105076. PubMed ID: 32659428
[TBL] [Abstract][Full Text] [Related]
6. HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.
Benoy V; Van Helleputte L; Prior R; d'Ydewalle C; Haeck W; Geens N; Scheveneels W; Schevenels B; Cader MZ; Talbot K; Kozikowski AP; Vanden Berghe P; Van Damme P; Robberecht W; Van Den Bosch L
Brain; 2018 Mar; 141(3):673-687. PubMed ID: 29415205
[TBL] [Abstract][Full Text] [Related]
7. Novel HDAC6 Inhibitors Increase Tubulin Acetylation and Rescue Axonal Transport of Mitochondria in a Model of Charcot-Marie-Tooth Type 2F.
Adalbert R; Kaieda A; Antoniou C; Loreto A; Yang X; Gilley J; Hoshino T; Uga K; Makhija MT; Coleman MP
ACS Chem Neurosci; 2020 Feb; 11(3):258-267. PubMed ID: 31845794
[TBL] [Abstract][Full Text] [Related]
8. Cell-specific role of histone deacetylase 6 in chemotherapy-induced mechanical allodynia and loss of intraepidermal nerve fibers.
Ma J; Trinh RT; Mahant ID; Peng B; Matthias P; Heijnen CJ; Kavelaars A
Pain; 2019 Dec; 160(12):2877-2890. PubMed ID: 31356453
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 6 inhibition restores autophagic flux to promote functional recovery after spinal cord injury.
Zheng Z; Zhou Y; Ye L; Lu Q; Zhang K; Zhang J; Xie L; Wu Y; Xu K; Zhang H; Xiao J
Exp Neurol; 2020 Feb; 324():113138. PubMed ID: 31794745
[TBL] [Abstract][Full Text] [Related]
10. HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving α-tubulin acetylation.
Song R; Yang Y; Lei H; Wang G; Huang Y; Xue W; Wang Y; Yao L; Zhu Y
J Mol Cell Cardiol; 2018 Nov; 124():58-69. PubMed ID: 30315806
[TBL] [Abstract][Full Text] [Related]
11. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy.
LaPointe NE; Morfini G; Brady ST; Feinstein SC; Wilson L; Jordan MA
Neurotoxicology; 2013 Jul; 37():231-9. PubMed ID: 23711742
[TBL] [Abstract][Full Text] [Related]
12. SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules.
Wang F; Zheng L; Yi Y; Yang Z; Qiu Q; Wang X; Yan W; Bai P; Yang J; Li D; Pei H; Niu T; Ye H; Nie C; Hu Y; Yang S; Wei Y; Chen L
Mol Cancer Ther; 2018 Apr; 17(4):763-775. PubMed ID: 29610282
[TBL] [Abstract][Full Text] [Related]
13. A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.
Onishi T; Maeda R; Terada M; Sato S; Fujii T; Ito M; Hashikami K; Kawamoto T; Tanaka M
Sci Rep; 2021 Jul; 11(1):15423. PubMed ID: 34326423
[TBL] [Abstract][Full Text] [Related]
14. Aberrant GlyRS-HDAC6 interaction linked to axonal transport deficits in Charcot-Marie-Tooth neuropathy.
Mo Z; Zhao X; Liu H; Hu Q; Chen XQ; Pham J; Wei N; Liu Z; Zhou J; Burgess RW; Pfaff SL; Caskey CT; Wu C; Bai G; Yang XL
Nat Commun; 2018 Mar; 9(1):1007. PubMed ID: 29520015
[TBL] [Abstract][Full Text] [Related]
15. Deacetylation of Miro1 by HDAC6 blocks mitochondrial transport and mediates axon growth inhibition.
Kalinski AL; Kar AN; Craver J; Tosolini AP; Sleigh JN; Lee SJ; Hawthorne A; Brito-Vargas P; Miller-Randolph S; Passino R; Shi L; Wong VSC; Picci C; Smith DS; Willis DE; Havton LA; Schiavo G; Giger RJ; Langley B; Twiss JL
J Cell Biol; 2019 Jun; 218(6):1871-1890. PubMed ID: 31068376
[TBL] [Abstract][Full Text] [Related]
16. HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice.
Picci C; Wong VSC; Costa CJ; McKinnon MC; Goldberg DC; Swift M; Alam NM; Prusky GT; Shen S; Kozikowski AP; Willis DE; Langley B
Exp Neurol; 2020 Jun; 328():113281. PubMed ID: 32147437
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment.
Ma J; Huo X; Jarpe MB; Kavelaars A; Heijnen CJ
Acta Neuropathol Commun; 2018 Oct; 6(1):103. PubMed ID: 30270813
[TBL] [Abstract][Full Text] [Related]
18. HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness.
Leyk J; Daly C; Janssen-Bienhold U; Kennedy BN; Richter-Landsberg C
Cell Death Dis; 2017 Aug; 8(8):e3028. PubMed ID: 29048427
[TBL] [Abstract][Full Text] [Related]
19. The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells.
Tu HJ; Lin YJ; Chao MW; Sung TY; Wu YW; Chen YY; Lin MH; Liou JP; Pan SL; Yang CR
Clin Epigenetics; 2018 Dec; 10(1):162. PubMed ID: 30594243
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation.
Dompierre JP; Godin JD; Charrin BC; Cordelières FP; King SJ; Humbert S; Saudou F
J Neurosci; 2007 Mar; 27(13):3571-83. PubMed ID: 17392473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
